Form 4: Igor Bilinsky, Iovance Biotherapeutics COO, Reports Stock Transactions
SEC Form 4 Filing
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On June 3, 2024, Igor Bilinsky, the Chief Operating Officer of Iovance Biotherapeutics, had 3,516 restricted stock units (RSUs) vest.
- The company withheld 1,784 shares to cover mandatory tax obligations at a price of $8.37 per share.
- Following these transactions, Bilinsky directly owns 39,758 shares of common stock and 24,613 restricted stock units.
- These remaining RSUs will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation and doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 03/02/2023 | Date of grant for the remaining RSUs held by the Reporting Person. |
| 06/03/2024 | Date of transaction: vesting of restricted stock units and tax withholding. |
| 06/05/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.